

1 **Fibrillin-1 Orchestrates a Pro-senescent Niche Driving Peritubular Endothelial**  
2 **Senescence via ZEB1/endothelin-1/ $\beta$ -catenin Signaling**

3 Junxin Huang<sup>#1,2</sup>, Xiaoyao Zhang<sup>#1,2</sup>, Zifu Yao<sup>#1,2</sup>, Yuxi Zhang<sup>1,2</sup>, Di Huang<sup>3</sup>,  
4 Yongsi Liu<sup>3</sup>, Fan Fan Hou<sup>1,2</sup>, Youhua Liu<sup>1,2\*</sup>, Li Li<sup>1,2\*</sup>

5 <sup>1</sup>State Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical  
6 Research Center for Kidney and Urological Diseases, Division of Nephrology, Nanfang  
7 Hospital, Southern Medical University, Guangzhou, China;

8 <sup>2</sup>Guangdong Provincial Key Laboratory of Renal Failure Research, Guangdong Provincial  
9 Institute of Nephrology, Guangzhou, China;

10 <sup>3</sup>Light Innovation Technology Ltd., Shenzhen, China.

11  
12  
13 Abstract: 186


14 Words: 7550

15  
16  
17 <sup>#</sup>These authors contributed equally.


18  
19  
20 <sup>\*</sup>To whom correspondence should be addressed:

21 Li Li, Ph.D or Youhua Liu, Ph.D, Division of Nephrology, Nanfang Hospital, Southern  
22 Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, China. E-mail:  
23 guilinlily3@i.smu.edu.cn or liuyh@smu.edu.cn

24 **Supplementary Figures**



25 **Figure S1. FBN1 induces endothelial cell senescence in vitro.** (A) Representative Western blots  
 26 showing the expression of p21, p16, and  $\gamma$ -H2AX proteins in HUVECs treated with increasing doses of  
 27 FBN1. (B) Quantitative data of p21, p16 and  $\gamma$ -H2AX proteins in HUVECs treated with increasing  
 28 doses of FBN1. \* $P < 0.05$  versus Ctrl (n = 3). (C) Quantitative data of p21, p16 and  $\gamma$ -H2AX proteins  
 29 in HUVECs after FBN1 stimulation at different time points. \* $P < 0.05$  versus Ctrl (n = 3). (D)  
 30 Quantitative data of SA- $\beta$ -gal positive area in different groups as indicated. \* $P < 0.05$  versus Ctrl (n =  
 31 6). (E) Quantitative data of the intensity of MitoSOX staining in different groups as indicated. \* $P <$   
 32 0.05 versus Ctrl (n = 3). (F-H) Quantitative data show the levels of segment, branch and mesh in tube  
 33 formation assays. \* $P < 0.05$  versus Ctrl (n = 6). (I) Quantitative data show the migration distance in  
 34 different groups. \* $P < 0.05$  versus Ctrl (n = 3). (J) The heatmap shows the gene expression in control  
 35 cells and FBN1-treated cells. (K-L) Representative Western blot (K) and quantitative data (L) show the  
 36 expression of p21, p16, and  $\gamma$ -H2AX proteins in HK-2 cells treated with FBN1. No significant  
 37 induction of these proteins was observed (n = 3), indicating that the pro-senescent effect of FBN1 is  
 38 specific to endothelial cells.



40 **Figure S2. ET-1/β-catenin axis conveys FBN1-derived pro-senescent signaling.** (A) Violin plots  
 41 displaying differences in Wnt/β-catenin signaling scores across endothelial subpopulations. Statistical  
 42 significance was assessed using the Wilcoxon rank-sum test. \*\*\*\* $P < 0.0001$ . (B) Quantitative data of  
 43 ET-1, active β-catenin, p21, p16 and γ-H2AX proteins in HUVECs treated with different  
 44 concentrations of ET-1. \* $P < 0.05$  versus Ctrl (n = 3). (C-D) Representative Western blot (B) and  
 45 quantitative data (C) show the expression of FN, IL-1β and IL-6 proteins in different groups as  
 46 indicated. \* $P < 0.05$  versus Ctrl, † $P < 0.05$  versus FBN1 (n = 3). (E) Quantitative data of ET-1, active  
 47 β-catenin, p21, p16 and γ-H2AX proteins in different groups as indicated. \* $P < 0.05$  versus Ctrl, † $P <$   
 48  $0.05$  versus FBN1 (n = 3).

49

50

51


52

53

54

55

56



57 **Figure S3. ZEB1 mediates FBN1-induced ET-1/β-catenin activation in endothelial senescence. (A)**  
 58 Quantitative data of ET-1, active β-catenin, p21, p16 and γ-H2AX proteins in primary endothelial cells  
 59 from different groups. \* $P < 0.05$  versus Ctrl, † $P < 0.05$  versus FBN1 (n = 3). **(B)** The expression of  
 60 *Zeb1* in capillary endothelial cells across three canonical CKD models (UIRI, UUO, AAN). \*\*\*\* $P <$   
 61 0.0001 versus Sham. **(C)** Quantitative data of ZEB1, ET-1 and active β-catenin proteins in different  
 62 groups as indicated. \* $P < 0.05$  versus NC, † $P < 0.05$  versus NC/FBN1 (n = 3).

63

64

65

66

67

68

69

70


71

72

73

74

75



76 **Figure S4. Knockout of *Fbn1* ameliorates microvascular hemodynamics in UUO mice.** (A)  
 77 Quantitative PCR analysis of *Fbn1* mRNA expression in whole kidney. \* $P < 0.05$  versus Sham-WT, †  
 78  $P < 0.05$  versus UUO-WT (n = 6). (B-C) Quantitative data of complexity level (B) and perfusion index  
 79 (C) of microvasculature in different groups as indicated. \* $P < 0.05$  versus Sham-WT, † $P < 0.05$  versus  
 80 UUO-WT (n = 3).

81

82

83

84

85

86

87

88

89


90

91


92

93

94



95 **Figure S5. FBN1 drives post-ischemic microvascular decay via senescence acceleration. (A-B)**  
 96 Serum creatinine (Scr) and blood urea nitrogen (BUN) levels in different groups as indicated. \**P* <  
 97 0.05 versus Sham-WT, †*P* < 0.05 versus UIRI-WT (n = 6). (C) Quantitative data of ZEB1, ET-1,  
 98 active  $\beta$ -catenin, EMCN, IL-1 $\beta$  and IL-6 proteins in different groups as indicated. \**P* < 0.05 versus  
 99 Sham-WT, †*P* < 0.05 versus UIRI-WT (n = 6). (D) Quantitative analyses of immunohistochemical  
 100 staining for FBN1 and EMCN. At least 10 randomly selected microscopic fields were assessed, and the  
 101 results were averaged for each kidney. \**P* < 0.05 versus Sham-WT, †*P* < 0.05 versus UIRI-WT (n = 6).  
 102 (E-F) Quantitative data show the fluorescence intensity of EMCN and FITC-dextran signals. \**P* < 0.05  
 103 versus Sham-WT, †*P* < 0.05 versus UIRI-WT (n = 6). (G-I) Quantitative data show the vessel ratio,  
 104 complexity level and perfusion index in different groups as indicated. \**P* < 0.05 versus Sham-WT, †*P*  
 105 < 0.05 versus UIRI-WT (n = 3). (J) Quantification of vascular spatial volume in cleared kidney tissues  
 106 (n = 1). (K) Quantitative data of ET-1, active  $\beta$ -catenin, p21, p16,  $\gamma$ -H2AX and EMCN proteins in  
 107 different groups of renal primary endothelial cells. \**P* < 0.05 versus Sham-WT, †*P* < 0.05 versus  
 108 UIRI-WT (n = 6). (L) Quantitative data of ET-1, active  $\beta$ -catenin, p21, p16,  $\gamma$ -H2AX and EMCN  
 109 proteins in HUVECs inoculated on different KTS. \**P* < 0.05 versus Sham-KTS-WT, †*P* < 0.05 versus  
 110 UIRI-KTS-WT (n = 3).



111 **Figure S6. FBN1 mediates endothelial senescence and microvascular rarefaction in folic acid**  
 112 **nephropathy. (A)** Quantitative data of FBN1, p53, p21, p16 and  $\gamma$ -H2AX proteins in different groups  
 113 as indicated. \* $P < 0.05$  versus Sham-WT, † $P < 0.05$  versus FA-WT (n = 6). **(B)** Quantitative data of  
 114 ZEB1, ET-1, active  $\beta$ -catenin, EMCN, IL-1 $\beta$  and IL-6 proteins in different groups as indicated. \* $P <$   
 115 0.05 versus Sham-WT, † $P < 0.05$  versus FA-WT (n = 6). **(C)** Quantitative analyses of  
 116 immunohistochemical staining for FBN1 and EMCN. At least 10 randomly selected microscopic fields  
 117 were assessed, and the results were averaged for each kidney. \* $P < 0.05$  versus Sham-WT, † $P < 0.05$   
 118 versus FA-WT (n = 6). **(D-E)** Quantitative data show the fluorescence intensity of EMCN and  
 119 FITC-dextran signals. \* $P < 0.05$  versus Sham-WT, † $P < 0.05$  versus FA-WT (n = 6).

120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130

131 **Supplementary Tables**132 **Supplementary Table S1. Publicly available single-cell datasets**

<b>GEO Sample</b>	<b>PMID</b>	<b>Mouse Strain</b>	<b>Sex</b>	<b>Age</b>	<b>Modeling methods</b>
GSM5333085	39414946	C57BL/6J	male	12 week	UUO-10D
GSM5333086	39414946	C57BL/6J	male	12 week	UUO-10D
CRX293624	35852860	C57BL/6J	male	7 week	Sham
CRX293625	35852860	C57BL/6J	male	7 week	Sham
CRX293626	35852860	C57BL/6J	male	7 week	Sham
CRX293627	35852860	C57BL/6J	male	7 week	AAN-3W
CRX293628	35852860	C57BL/6J	male	7 week	AAN-3W
CRX293629	35852860	C57BL/6J	male	7 week	AAN-3W
CRA022333	41042124	C57BL/6J	male	8 week	Sham
CRA022333	41042124	C57BL/6J	male	8 week	Sham
CRA022333	41042124	C57BL/6J	male	8 week	UIRI-10D
CRA022333	41042124	C57BL/6J	male	8 week	UIRI-10D

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

**Supplementary Table S2.** The sources of antibodies used in this study

<b>Antibodies</b>	<b>Catalogue number</b>	<b>Company</b>	<b>Location</b>
<b>Primary antibodies</b>			
anti-FBN1	Ab53076	Abcam	Cambridge, MA
anti-FBN1	NBP2-16493	Novus Biologicals	Littleton, CO
anti- $\gamma$ -H2AX	Ab26350	Abcam	Cambridge, MA
anti-EMCN	AF4666	R & D Systems	Minneapolis, MN
anti-EMCN	A14131	Abclonal	Wuhan, China
anti-p21	A2691	ABclonal	Wuhan, China
anti-p16	Sc-1661	Santa Cruz Biotechnology	Santa Cruz, CA
anti-ET-1	AB2786	Abcam	Cambridge, MA
anti-active $\beta$ -catenin	19807S	Cell Signaling Technology	Danvers, MA
anti- $\beta$ -catenin	610154	BD biosciences	San Jose, CA
anti-ZEB1	21544-1-AP	Proteintech Group	Wuhan, China
anti-p53	2524S	Cell Signaling Technology	Danvers, MA
anti-IL-1 $\beta$	A27676	Abclonal	Wuhan, China
anti-IL-6	A0286	Abclonal	Wuhan, China
anti-FN	F3648	Sigma-Aldrich	St. Louis, MO
anti- $\alpha$ -Tubulin	RM2007	Ray Antibody Biotech	Peachtree Corners, GA
<b>Secondary antibodies</b>			
Goat anti-mouse	115-035-003	Jackson Laboratories	West Grove, PA
Goat anti-rabbit	305-035-003	Jackson Laboratories	West Grove, PA
Donkey anti-goat	705-065-147	Jackson Laboratories	West Grove, PA

150

151

152

153

154

155

156

157

158

**Supplementary Table S3.** Nucleotide sequences of the primers used for qPCR

Species	Gene	Primer Sequence 5' to 3'	
		Forward	Reverse
<i>Homo</i>	<i>TNF</i>	CCTCTCTCTAATCAGCCCTCTG	GAGGACCTGGGAGTAGATGAG
<i>Homo</i>	<i>IL1B</i>	ATGATGGCTTATTACAGTGGCAA	GTCGGAGATTTCGTAGCTGGA
<i>Homo</i>	<i>IL6</i>	ACTCACCTCTTCAGAACGAATTG	CCATCTTTGGAAGGTTTCAGGTTG
<i>Homo</i>	<i>CXCL8</i>	TTTTGCCAAGGAGTGCTAAAGA	AACCCTCTGCACCCAGTTTTTC
<i>Homo</i>	<i>EDN1</i>	AAGGCAACAGACCGTGAAAAT	CGACCTGGTTTTGTCTTAGGTG
<i>Homo</i>	<i>ZEB1</i>	TTACACCTTTGCATACAGAACCC	TTTACGATTACACCCAGACTGC
<i>Homo</i>	<i>ACTB</i>	CTCACCATGGATGATGATATCGC	AGGAATCCTTCTGACCCATGC
<i>Mus</i>	<i>Edn1</i>	GCACCGGAGCTGAGAATGG	GTGGCAGAAGTAGACACACTC
<i>Mus</i>	<i>Il1b</i>	GCAACTGTTCTGAACCTCAACT	ATCTTTTGGGGTCCGTCAACT
<i>Mus</i>	<i>Il6</i>	TAGTCCTTCCTACCCCAATTCC	TTGGTCCTTAGCCACTCCTTC
<i>Mus</i>	<i>Ccl8</i>	TCTACGCAGTGCTTCTTTGCC	AAGGGGGATCTTCAGCTTTAGTA
<i>Mus</i>	<i>Actb</i>	CAGCTGAGAGGGAAATCGTG	CGTTGCCAATAGTGATGACC

160

161